Organizational Changes at Galderma

Galderma named a new president of Galderma Laboratories, L.P. along with a new leadership team in anticipation of several new product launches in the upcoming months.
 
North America is a keystone of Galderma's activity, as well as its largest market. Under the leadership of Stuart Raetzman, Galderma has recently aligned the North American affiliate structure to the company's global strategy, transitioning into an organization with three specific business units: prescription medications; self-medication products; and aesthetic & corrective medical solutions.
 
By way of personal care, in the Prescription Business Unit,  Galderma offers a comprehensive portfolio of rosacea treatments comprising three products with distinctive delivery modes and indications: topical Mirvaso Gel for persistent facial erythema associated with rosacea, systemic Oracea Capsules, the only oral rosacea treatment approved by FDA, as well as Soolantra Cream, the latest advancement in rosacea treatment. In late December 2014, the FDA approved Soolantra® Cream, a once-daily, antibiotic-free product indicated for the treatment of inflammatory lesions, or bumps and pimples, of rosacea.
 
The Self-Medication Business Unit includes non-prescription, cosmetic and over-the-counter drug brands. These products include the iconic brand Cetaphil (cleansers and moisturizers) and Cetaphil Baby, the most recent addition to the line. Galderma's first over-the-counter acne regimen, Benzac Acne Solutions, was launched on Jan 5, as previously reported in Happi.
 
The new leadership team includes:
 
Todd Zavodnick, former vice president and general manager for the Aesthetic and Corrective business, has been appointed president and general manager of Galderma Laboratories, L.P. During the past 10 years, he held leadership roles in Asia, Europe, Middle East, Africa, and Latin America for Alcon Laboratories and Galderma Laboratories. In the interim, Zavodnick will continue leading the Aesthetic and Corrective Business Unit. A new vice president will be appointed in the upcoming months.
 
Safia Rizvi is vice president and general manager of US Prescription Business Unit. She was formally the managing director and general manager of UCB Pharmaceuticals in Mumbai, India.
 
Miles Harrison has been named vice president and general manager US Self-Medication Business.  Miles Harrison joined Galderma from Novartis.
 
Dr. Philip Brown MD, JD, continues to serve as senior vice president of Medical and Regulatory Affairs.